Aripiprazole LA-Risperidone
From Psychiatrienet
| ||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||
Switch medication from Aripiprazole LA to Risperidone[4][5][6]
Stop Aripiprazole LA - Day 1: Last depot injection
Start Risperidone- t= 0 Start dosing 25% of the target dose on the day you normally would have injected the former depot.
- t= 1 x T1/2 of depot approx. 50% of target dose
- t= 2 x T1/2 of depot approx. 75% of target dose
- t= 3 x T1/2 of depot approx. 100% of target dose
- See 'more information' for the T1/2 of this depot
- the T1/2 of aripiprazole depot is 46.5 days after administration of 400 mg and approximately 29.9 days after adminstration of 300 mg.[7]
More information- More information you'll find in the summary of product characteristics (SPC) of aripiprazole depot injection. [8]
- Aripiprazol Abilify Maintena is a prolonged release suspension for injection and is available in 300mg and 400mg (once a month) and 720mg and 960mg (once every two months).
- ↑ 1.0 1.1 KNMP; Informatorium Medicamentorum 2023; Monografie "risperidon" (Dutch)
- ↑ Woods SW; Chlorpromazine equivalent doses for the newer atypical antipsychotics J Clin Psychiatry 2003;64:663-667
- ↑ 3.0 3.1 The Lundbeck Institute; Psychotropics; Terminal Plasma Half-lives
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ A. Risselada, Switchen van en naar depotantipsychotica - een update; Psyfar, june 2022 nummer 2
- ↑ KNMP Kennisbank, informatorium medicamentorum: Aripiprazol
- ↑ https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena SPC of the European Medicines Agency on aripiprazole depot
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
